Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 5-6/2013

01.03.2013 | Themenschwerpunkt

Transarterielle perkutane Chemoembolisation beim Leberzellkarzinom

verfasst von: Dr. Johannes Petersen, Benjamin Henninger, Bernhard Glodny, Werner Jaschke

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 5-6/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das hepatozelluläre Karzinom stellt in der westlichen Welt eines der häufigsten tumorbedingten Todesursachen dar. Der vorliegende Artikel befasst sich mit der transarteriellen Chemoembolisation (TACE) als palliative Behandlungsmethode.
Die TACE verfolgt 2 verschiedene therapeutische Ansätze. Es wird kombiniert eine lokale Chemotherapie über die das HCC versorgende Arterie appliziert und anschließend eine Devaskularisation des Tumors durch ein selektives Verschließen der zuführenden Arterie durchgeführt. Verschiedene Embolisationstechniken und Zytostatika werden beschrieben. Die TACE stellt eine sichere und gering invasive Therapiemaßnahme dar. Die häufigste Nebenwirkung stellt das Postembolisationssyndrom dar mit den klinischen Symptomen Übelkeit, Erbrechen, Fieber und Bauchschmerzen bis hin zu einem sehr selten auftretendem Leberversagen.
Das Therapieziel ist die Progression der Tumorerkrankung zu unterbinden, das progressionsfreie Intervall zu verlängern und die Lebensqualität zu erhalten. Weitere Therapieindikationen stellen das Überbrücken des Zeitraumes bis zur Lebertransplantation und das Konzept der neoadjuvanten Behandlung dar.
Die TACE gilt daher als eine wichtige Behandlungsoption des HCC. Die Therapieindikation sollte jedoch individuell durch ein interdisziplinäres Tumorboard gestellt werden.
Literatur
1.
Zurück zum Zitat Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumors. J Hepatol. 2002;37:805–13.CrossRef Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumors. J Hepatol. 2002;37:805–13.CrossRef
2.
Zurück zum Zitat Poon RTP, Fan ST, Wong J. Risk factors, prevention and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232:10–24.CrossRef Poon RTP, Fan ST, Wong J. Risk factors, prevention and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232:10–24.CrossRef
3.
Zurück zum Zitat Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–38.PubMedCrossRef Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–38.PubMedCrossRef
4.
Zurück zum Zitat Cho YK, Kim WT, Chung JW. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2010;51:1116–8.CrossRef Cho YK, Kim WT, Chung JW. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2010;51:1116–8.CrossRef
5.
6.
Zurück zum Zitat Clark HP, Carson WF, Kavanagh PV, Ho CP, Shen P, Zagoria RJ. Staging and current treatment of hepatocellular carcinoma. Radiographics. 2005;25(Suppl):3–23.CrossRef Clark HP, Carson WF, Kavanagh PV, Ho CP, Shen P, Zagoria RJ. Staging and current treatment of hepatocellular carcinoma. Radiographics. 2005;25(Suppl):3–23.CrossRef
7.
Zurück zum Zitat Wible BC, Rilling WS, Drescher P, Hieb RA, Saeian K, Frangakis C, Chen Y, Eastwood D, Kim HS. Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. J Vasc Interv Radiol. 2010;21:1024–30.PubMedCrossRef Wible BC, Rilling WS, Drescher P, Hieb RA, Saeian K, Frangakis C, Chen Y, Eastwood D, Kim HS. Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. J Vasc Interv Radiol. 2010;21:1024–30.PubMedCrossRef
8.
Zurück zum Zitat Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J, Perrin H, Azoulay D. Influence of preoperative transarterial lipiodol chemoembolizationon resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg. 1997;226:688–701.PubMedCrossRef Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J, Perrin H, Azoulay D. Influence of preoperative transarterial lipiodol chemoembolizationon resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg. 1997;226:688–701.PubMedCrossRef
9.
Zurück zum Zitat Sugo H, Futagawa S, Beppu T, Fukasawa M, Kojima K. Role of preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: relation between postoperative course and the pattern of tumor recurrence. World J Surg. 2003;27:1295–9.PubMedCrossRef Sugo H, Futagawa S, Beppu T, Fukasawa M, Kojima K. Role of preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: relation between postoperative course and the pattern of tumor recurrence. World J Surg. 2003;27:1295–9.PubMedCrossRef
10.
Zurück zum Zitat Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, Margreiter R, Vogel W. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl. 2003;9:557–63.PubMedCrossRef Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, Margreiter R, Vogel W. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl. 2003;9:557–63.PubMedCrossRef
11.
Zurück zum Zitat Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6–25.PubMedCrossRef Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6–25.PubMedCrossRef
12.
Zurück zum Zitat Vogl TJ, Trapp M, Schroeder H, Mack M, Schuster A, Schmitt J, Neuhaus P, Felix R. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. Radiology. 2000;214:349–57.PubMed Vogl TJ, Trapp M, Schroeder H, Mack M, Schuster A, Schmitt J, Neuhaus P, Felix R. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. Radiology. 2000;214:349–57.PubMed
13.
Zurück zum Zitat Bonomo G, Pedicini V, Maonfardini L, Della Vigna P, Poretti D, Orgera G, Orsi F. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol. 2010;33:552–9.PubMedCrossRef Bonomo G, Pedicini V, Maonfardini L, Della Vigna P, Poretti D, Orgera G, Orsi F. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol. 2010;33:552–9.PubMedCrossRef
14.
Zurück zum Zitat Lammer J, Malagari K, Vogl TJ, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33;41–52. Lammer J, Malagari K, Vogl TJ, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33;41–52.
15.
Zurück zum Zitat Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, Denys A, Lee C. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. Am J Roentgenol. 2011;197:W562–70.CrossRef Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, Denys A, Lee C. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. Am J Roentgenol. 2011;197:W562–70.CrossRef
16.
Zurück zum Zitat Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniozou A, Marinis A, Kelekis A, Alexopoulou E, Chatziioannou A, Chatzimichael K, Dourakis S, Kelekis N, Rizos S, Kelekis D. Chemoembolization with doxurubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol. 2012; Epub ahead of print. Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniozou A, Marinis A, Kelekis A, Alexopoulou E, Chatziioannou A, Chatzimichael K, Dourakis S, Kelekis N, Rizos S, Kelekis D. Chemoembolization with doxurubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol. 2012; Epub ahead of print.
17.
Zurück zum Zitat Lencioni R, de Baere T, Burrel M, Caridi JG, Lammer J, Malagari K, Martin RC, O’Grady E, Real MI, Vogl TJ, Watkinson A, Geschwind JF. Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol. 2011; Epub ahead of print. Lencioni R, de Baere T, Burrel M, Caridi JG, Lammer J, Malagari K, Martin RC, O’Grady E, Real MI, Vogl TJ, Watkinson A, Geschwind JF. Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol. 2011; Epub ahead of print.
18.
Zurück zum Zitat Lee JK, Chung YH, Song BC, Shin JW, Choi WB, Yang SH, Yoon HK, Sung KB, Lee YS, Suh DJ. Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol. 2002;17:52–8.PubMedCrossRef Lee JK, Chung YH, Song BC, Shin JW, Choi WB, Yang SH, Yoon HK, Sung KB, Lee YS, Suh DJ. Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol. 2002;17:52–8.PubMedCrossRef
19.
Zurück zum Zitat Grieco A, Marcoccia S, Miele L, Marmirol L, Caminiti G, Ragazzoni E, Cotroneo AR, Cefaro GA, Rapaccini GL, Gasbarrini G. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival. Hepato-gastroenterol 2003;50:207–12. Grieco A, Marcoccia S, Miele L, Marmirol L, Caminiti G, Ragazzoni E, Cotroneo AR, Cefaro GA, Rapaccini GL, Gasbarrini G. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival. Hepato-gastroenterol 2003;50:207–12.
20.
Zurück zum Zitat Rossi S, Garbagnati F, Lencioni R, Allgaier HP, Marchianò A, Fornari F, Quaretti P, Tolla GD, Ambrosi C, Mazzaferro V, Blum HE, Bartolozzi C. Percutaneous radio-frequency thermal ablation of non-resectable hepatocellular carcinoma after occlusion of tumor supply. Radiology. 2000;217:119–26.PubMed Rossi S, Garbagnati F, Lencioni R, Allgaier HP, Marchianò A, Fornari F, Quaretti P, Tolla GD, Ambrosi C, Mazzaferro V, Blum HE, Bartolozzi C. Percutaneous radio-frequency thermal ablation of non-resectable hepatocellular carcinoma after occlusion of tumor supply. Radiology. 2000;217:119–26.PubMed
21.
Zurück zum Zitat Takamura M, Murakami T, Shibata T, Ishida T, Niinobu T, Kawata S, Shimizu J, Kim T, Monden M, Nakamura H. Microwave coagulation therapy with interruption of hepatic blood in- or outflow: an experimental study. J Vasc Interv Radiol. 2001;12:619–22.PubMedCrossRef Takamura M, Murakami T, Shibata T, Ishida T, Niinobu T, Kawata S, Shimizu J, Kim T, Monden M, Nakamura H. Microwave coagulation therapy with interruption of hepatic blood in- or outflow: an experimental study. J Vasc Interv Radiol. 2001;12:619–22.PubMedCrossRef
22.
Zurück zum Zitat Gerunda GE, Neri D, Merenda R, Barbazza F, Zangrandi F, Meduri F, Bisello M, Valmoasoni M, Gangemi A, Faccioli AM. Role of transarterial chemoembolization before liver resection for hepatocarcinoma. Liver Transpl. 2000;6:619–26.PubMedCrossRef Gerunda GE, Neri D, Merenda R, Barbazza F, Zangrandi F, Meduri F, Bisello M, Valmoasoni M, Gangemi A, Faccioli AM. Role of transarterial chemoembolization before liver resection for hepatocarcinoma. Liver Transpl. 2000;6:619–26.PubMedCrossRef
23.
Zurück zum Zitat Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, Mancini R, Sperduti I, Pizzi G, Diodoro MG, Perrone M, Giampalma E, Angelelli B, Fiore F, Lastoria S, Bacchetti S, Gasperini D, Geatti O, Izzo F. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer. 2010;103:324–31.PubMedCrossRef Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, Mancini R, Sperduti I, Pizzi G, Diodoro MG, Perrone M, Giampalma E, Angelelli B, Fiore F, Lastoria S, Bacchetti S, Gasperini D, Geatti O, Izzo F. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer. 2010;103:324–31.PubMedCrossRef
24.
Zurück zum Zitat Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V. Randomised trial of SIR-spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12:1711–20.PubMedCrossRef Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V. Randomised trial of SIR-spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12:1711–20.PubMedCrossRef
25.
Zurück zum Zitat Soulen MC. Image-guided therapy of hepatic malignancies. Appl Radiol. 2000;29:21–2.CrossRef Soulen MC. Image-guided therapy of hepatic malignancies. Appl Radiol. 2000;29:21–2.CrossRef
26.
Zurück zum Zitat Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol. 2001;12:321–26.PubMedCrossRef Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol. 2001;12:321–26.PubMedCrossRef
27.
Zurück zum Zitat Patel NH, Hahn D, Rapp S, Bergan K, Coldwell DM. Hepatic artery embolization: factors predisposing to postembolization pain and nausea. J Vasc Interv Radiol. 2000;11:453–60.PubMedCrossRef Patel NH, Hahn D, Rapp S, Bergan K, Coldwell DM. Hepatic artery embolization: factors predisposing to postembolization pain and nausea. J Vasc Interv Radiol. 2000;11:453–60.PubMedCrossRef
28.
Zurück zum Zitat Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10:115–20.CrossRef Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10:115–20.CrossRef
29.
Zurück zum Zitat Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, Gasbarrini G. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut. 2005;54:411–8.PubMedCrossRef Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, Gasbarrini G. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut. 2005;54:411–8.PubMedCrossRef
Metadaten
Titel
Transarterielle perkutane Chemoembolisation beim Leberzellkarzinom
verfasst von
Dr. Johannes Petersen
Benjamin Henninger
Bernhard Glodny
Werner Jaschke
Publikationsdatum
01.03.2013
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 5-6/2013
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-013-0180-x

Weitere Artikel der Ausgabe 5-6/2013

Wiener Medizinische Wochenschrift 5-6/2013 Zur Ausgabe

Themenschwerpunkt

Übersicht: Lebertumore